RAPIDe-1
92 evidence topics · 15 sources
Objective
Study aim in the publication
Registry brief summary
Primary objective: symptom relief within 4 hours
Location and study date
Sites, regions, and screening and randomization dates in the publication
Countries and sites at topline, December 2022
U.S. clinical hold in August 2022 and partial lift for RAPIDe-1
Study design
Two-part, randomized, double-blind, placebo-controlled, crossover, dose-ranging design
Randomization to dose cohorts and crossover treatment sequences
Investigator confirmation of each attack by remote consultation
Safety visits, end-of-trial visit, and electronic attack diary
Rollover to CHAPTER-1 or RAPIDe-2 after the trial
Eligibility criteria
Inclusion criteria in the publication: age, HAE type, and attack frequency
Long-term prophylaxis exclusion and washout periods
Hepatic and renal function, CYP3A4 inhibitors or inducers, and pregnancy
Registry key inclusion and exclusion criteria
Treatment
Part 1 single dose in the attack-free state and Part 2 home self-administration
Registry interventions: soft capsules and matching placebo
Rescue medication permitted from 4 hours after study drug
Dose selection based on the bradykinin challenge and EC85
Study outcomes
Rationale for using change in the 3-Symptom composite visual analogue scale score as the primary endpoint
Primary endpoint: definition and assessment schedule in the publication
Electronic, numerically assisted capture of the VAS-3
Authors' rationale: 4-hour timepoint and scales used in earlier on-demand trials
Sponsor rationale: VAS in icatibant and recombinant C1 esterase inhibitor approvals and the FDA outcome assessment compendium
Three-symptom VAS in the icatibant FAST-1 and FAST-2 trials
“Patients presenting with cutaneous or abdominal attacks were asked to evaluate the severity of three specific symptoms (cutaneous swelling, cutaneous pain, and abdominal pain) on a visual-analogue scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A composite score on the visual-analogue scale was calculated by taking the average of the three scores for the main symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and defining symptom relief as a 50% reduction from the baseline score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of the composite scores, the median time to symptom relief was 2.5 hours with icatibant versus 7.0 hours with placebo (P = 0.02) in FAST-1 and 2.0 hours with icatibant versus 15.0 hours with tranexamic acid (P<0.001) in FAST-2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Content validity of HAE VAS instruments
“It demonstrated the content validity of the four anatomical location HAE VAS instruments and their suitability for use in clinical trials of recombinant human C1INH (rhC1INH) treatment for ascertaining trial participants' assessments of the severity of acute angioedema symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
VAS-3 in earlier on-demand trials and its adaptation to electronic AMRA instruments
“The visual analog scale 3-symptom (VAS-3) and 5-symptom (VAS-5) are PROs that have also been used in earlier clinical trials of ODTs for HAE to derive key endpoints for clinical outcomes, such as a ≥30% or ≥50% reduction in symptom severity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, VAS-3 and VAS-5 were adapted into electronic assessments and renamed AMRA-3 (used for non-upper-airway attacks) and AMRA-5 (used for upper-airway attacks, including laryngeal attacks) and, therefore, require content validation and assessment of their psychometric properties in the HAE population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoints: time-to-event VAS-3 outcomes, MSCS, and TOS
Key secondary endpoint: registry definition of almost complete or complete symptom relief
Key secondary endpoints: MSCS and TOS instruments
Key secondary endpoints: validation and minimally important differences of TOS and MSCS
“Anchor- and distribution-based analyses suggested that conservative estimates for MID are 30 points for TOS and -0.30 points for 4-h change in MSCS score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The psychometric tests performed here provide evidence of the reliability and validity of the TOS and MSCS for evaluating symptom severity and change in HAE patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other secondary endpoints: rescue medication use and lower-ranked endpoints including TSQM
Other secondary endpoint: TSQM registry definition
Post hoc endpoint: time to end of progression
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and power assumptions
Registry enrollment and participants randomized per dose cohort
Participants and attacks in the primary efficacy analysis
Participants and attacks in the safety analysis set
Attacks in the final analysis and participants with pharmacokinetic sampling
Description of analysis sets
Full analysis set
Safety and pharmacokinetic analysis sets
Primary analysis before all participants had three attacks, and descriptive final analysis
Primary endpoint model: mixed model for repeated measures
Multiplicity control for the 20 mg and 30 mg branches, and descriptive 10 mg analyses
Time-to-event and rescue medication analyses
Registry caveat on Kaplan-Meier medians
Results
Participant disposition
Screening, randomization, and follow-up in the primary analysis set
Registry participant flow by randomized dose cohort, Part I and Part II
| Milestone | Deucrictibant 10 mg cohort | Deucrictibant 20 mg cohort | Deucrictibant 30 mg cohort |
|---|---|---|---|
| Part I started | “24” | “25” | “25” |
| Part I completed | “24” | “24” | “25” |
| Part I withdrawal by subject | “0” | “1” | “0” |
| Part II started | “24” | “24” | “25” |
| Part II completed | “16” | “12” | “12” |
| Part II not completed | “8” | “12” | “13” |
| Part II withdrawal by subject | “2” | “3” | “5” |
| Part II not completed: “Participants Met Primary Analysis Criteria” | “6” | “9” | “8” |
Baseline characteristics
Demographics and HAE characteristics by dose cohort, full analysis set
| Characteristic | Deucrictibant 10 mg (n=24) | Deucrictibant 20 mg (n=25) | Deucrictibant 30 mg (n=25) |
|---|---|---|---|
| Age, years, median (IQR) | “44 (31–53)” | “45 (36–57)” | “39 (25–53)” |
| Female, n (%) | “17 (71%)” | “17 (68%)” | “15 (60%)” |
| White, n (%) | “22 (92%)” | “24 (96%)” | “25 (100%)” |
| HAE-C1INH type 1, n (%) | “19 (79%)” | “22 (88%)” | “24 (96%)” |
| HAE-C1INH type 2, n (%) | “5 (21%)” | “2 (8%)” | “1 (4%)” |
| Time since diagnosis, years, median (IQR) | “18 (10–26)” | “21 (13–37)” | “23 (10–37)” |
| More than 4 attacks in the 4 months before screening, n (%) | “20 (83%)” | “20 (80%)” | “20 (80%)” |
| Long-term prophylactic treatment history, n (%) | “3 (13%)” | “5 (20%)” | “5 (20%)” |
Attack frequency and prior HAE medication, full analysis set
Registry baseline age and ethnicity, full analysis set
Sex and race, mITT analysis set of 62 participants
Pre-treatment VAS-3 scores of treated attacks, mITT analysis set
| Treatment of the attack | Attacks | Pre-treatment VAS-3, mean (SD) |
|---|---|---|
| Deucrictibant 10 mg | “37” | “26·16 (11·67)” |
| Deucrictibant 20 mg | “28” | “25·46 (10·00)” |
| Deucrictibant 30 mg | “31” | “29·73 (13·53)” |
| Placebo | “51” | “27·76 (11·25)” |
Efficacy results
Primary endpoint: change in VAS-3 at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set of 147 attacks in 62 participants
| Measure | Deucrictibant 10 mg (n=21) | Deucrictibant 20 mg (n=16) | Deucrictibant 30 mg (n=20) | Placebo (n=51) |
|---|---|---|---|---|
| Attacks with VAS-3 at 4 h | “33” | “27” | “30” | “43” |
| VAS-3 at 4 h, mean (SD) | “12·09 (14·47)” | “11·93 (9·97)” | “14·71 (10·51)” | “30·09 (18·20)” |
| LSM difference vs placebo (95% CI) | “−16·75 (−21·52 to −11·97)” | “−15·02 (−20·22 to −9·81)” | “−16·28 (−21·27 to −11·29)” | Not applicable |
| p value | Not reported | “<0·0001” | “<0·0001” | Not applicable |
Primary endpoint: registry least squares mean change and nominal p value for 10 mg, participants with evaluable data
| Group | Participants | LS mean change in VAS-3 (SE) | LS mean difference vs placebo (95% CI) | p value |
|---|---|---|---|---|
| Deucrictibant 10 mg | “21” | “-14.83”( “1.833”) | “-16.75”( “-21.52”to “-11.97”) | “< 0.0001”, “Nominal p-value” |
| Deucrictibant 20 mg | “16” | “-13.10”( “2.111”) | “-15.02”( “-20.22”to “-9.81”) | “< 0.0001” |
| Deucrictibant 30 mg | “20” | “-14.37”( “1.975”) | “-16.28”( “-21.27”to “-11.29”) | “< 0.0001” |
| Placebo | “51” | “1.92”( “1.596”) | Not applicable | Not applicable |
Primary endpoint: sensitivity analyses and VAS-3 course over time
Primary endpoint: post hoc pooled deucrictibant doses versus placebo
Key secondary endpoints: multiplicity-controlled results for 20 mg and 30 mg
Key secondary endpoints: time to symptom relief, 50% reduction, and resolution by VAS-3, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
| Endpoint and measure | Deucrictibant 10 mg (37 attacks) | Deucrictibant 20 mg (28 attacks) | Deucrictibant 30 mg (31 attacks) | Placebo (51 attacks) |
|---|---|---|---|---|
| Onset of symptom relief (≥30% VAS-3 reduction), median h (95% CI) | “2·1 (1·5 to 2·9)” | “2·7 (1·9 to 3·5)” | “2·5 (1·9 to 3·8)” | “8·0 (7·6 to NE)” |
| Onset of symptom relief, hazard ratio (95% CI) | “3·81 (2·01 to 7·20)” | “3·08 (1·50 to 6·30)” | “3·61 (2·10 to 6·19)” | Not applicable |
| Onset of symptom relief, p value | Not reported | “0·0021” | “<0·0001” | Not applicable |
| ≥50% VAS-3 reduction, median h (95% CI) | “3·3 (2·4 to 3·9)” | “4·0 (2·9 to 6·0)” | “4·0 (3·3 to 5·8)” | “22·8 (20·0 to 24·1)” |
| ≥50% VAS-3 reduction, hazard ratio (95% CI) | “4·55 (2·41 to 8·59)” | “3·65 (1·80 to 7·38)” | “3·87 (2·26 to 6·63)” | Not applicable |
| ≥50% VAS-3 reduction, p value | Not reported | “0·0003” | “<0·0001” | Not applicable |
| Almost complete or complete symptom relief, median h (95% CI) | “5·8 (3·6 to 7·5)” | “20·0 (4·5 to 20·0)” | “20·0 (6·0 to 20·1)” | “42·0 (22·0 to NE)” |
| Almost complete or complete symptom relief, hazard ratio (95% CI) | “5·09 (2·81 to 9·22)” | “2·25 (1·19 to 4·27)” | “2·65 (1·61 to 4·38)” | Not applicable |
| Almost complete or complete symptom relief, p value | Not reported | “0·013” | “<0·0001” | Not applicable |
Key secondary endpoints: change in MSCS score and TOS at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
| Endpoint and measure | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Placebo |
|---|---|---|---|---|
| MSCS, attacks | “32” | “26” | “27” | “40” |
| MSCS, mean change from pre-treatment (SD) | “−1·08 (0·13)” | “−0·91 (0·14)” | “−0·68 (0·14)” | “−0·29 (0·11)” |
| MSCS, LSM difference vs placebo (95% CI) | “−0·79 (−1·11 to −0·46)” | “−0·61 (−0·97 to −0·26)” | “−0·39 (−0·73 to −0·04)” | Not applicable |
| MSCS, p value | Not reported | “0·0008” | “0·029” | Not applicable |
| TOS, attacks | “32” | “25” | “28” | “40” |
| TOS, mean (SD) score | “57·03 (58·63)” | “62·67 (36·09)” | “68·75 (38·86)” | “−2·71 (62·49)” |
| TOS, LSM difference vs placebo (95% CI) | “64·13 (40·35 to 87·91)” | “62·69 (36·71 to 88·67)” | “71·06 (46·09 to 96·03)” | Not applicable |
| TOS, p value | Not reported | “<0·0001” | “<0·0001” | Not applicable |
Symptom resolution within 24 hours without rescue medication, deucrictibant 20 and 30 mg versus placebo
Rescue medication use within 12, 24, and 48 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set
| Window and measure | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Placebo |
|---|---|---|---|---|
| Within 12 h, attacks with rescue medication, n (%) | “7 (19%)” | “3 (11%)” | “2 (7%)” | “31 (61%)” |
| Within 12 h, OR vs placebo (95% CI) | “0·15 (0·06 to 0·37)” | “0·08 (0·02 to 0·35)” | “0·04 (0·01 to 0·18)” | Not applicable |
| Within 24 h, attacks with rescue medication, n (%) | “9 (24%)” | “3 (11%)” | “4 (13%)” | “37 (73%)” |
| Within 24 h, OR vs placebo (95% CI) | “0·12 (0·05 to 0·29)” | “0·05 (0·01 to 0·19)” | “0·06 (0·02 to 0·18)” | Not applicable |
| Within 48 h, attacks with rescue medication, n (%) | “9 (24%)” | “4 (14%)” | “5 (16%)” | “37 (73%)” |
| Within 48 h, OR vs placebo (95% CI) | “0·12 (0·05 to 0·29)” | “0·07 (0·02 to 0·24)” | “0·07 (0·02 to 0·22)” | Not applicable |
Rescue medication use in the top-line data, December 2022, deucrictibant 10, 20, and 30 mg versus placebo
Time to onset of primary symptom relief by 30% VAS reduction, registry results, participants with evaluable data
Post hoc time to end of progression, deucrictibant 10, 20, and 30 mg versus placebo, 147 attacks in 62 participants
Results by attack location: abdominal, peripheral, and combined attacks
Final analysis of 165 attacks
Company characterization of efficacy across all three doses
Part 1 pharmacokinetics relative to EC85, 12 participants with sampling
Health-related quality of life and patient-reported outcomes
TSQM domain scores at 48 hours, registry results, participants with evaluable data
| Group | Participants | Effectiveness, mean (SD) | Convenience, mean (SD) | Satisfaction, mean (SD) |
|---|---|---|---|---|
| Deucrictibant 10 mg | “21” | “79.17”( “23.179”) | “80.56”( “16.569”) | “82.50”( “18.907”) |
| Deucrictibant 20 mg | “16” | “70.45”( “30.290”) | “83.08”( “23.096”) | “80.68”( “29.702”) |
| Deucrictibant 30 mg | “20” | “72.92”( “23.085”) | “77.55”( “20.229”) | “76.74”( “22.113”) |
| Placebo | “51” | “65.38”( “23.532”) | “76.07”( “27.441”) | “64.10”( “24.623”) |
Safety results
Part 1 adverse events in the attack-free state, safety analysis set of 72 participants
Treatment-emergent adverse events within 5 days by part and dose, safety analysis set
| Event | Part 1, 10 mg (n=23) | Part 1, 20 mg (n=24) | Part 1, 30 mg (n=25) | Part 2, 10 mg (38 attacks; n'=21) | Part 2, 20 mg (29 attacks; n'=16) | Part 2, 30 mg (36 attacks; n'=22) | Part 2, placebo (53 attacks; n'=53) |
|---|---|---|---|---|---|---|---|
| Any treatment-emergent adverse event | “2 (9%)” | “2 (8%)” | “4 (16%)” | “3 (8%)”, “3 (14%)” | “1 (3%)”, “1 (6%)” | “2 (6%)”, “2 (9%)” | “3 (6%)”, “3 (6%)” |
| Any treatment-related treatment-emergent adverse event | “1 (4%)” | “1 (4%)” | “0” | “0” | “0” | “1 (3%)”, “1 (5%)” | “1 (2%)”, “1 (2%)” |
Severe, serious, and discontinuation events, laboratory, ECG, and vital signs
Registry adverse event counts by part and treatment group
| Event group | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| Part I, 10 mg (participants) | “0”of “23” | “0”of “23” | “2”of “23” |
| Part I, 20 mg (participants) | “0”of “24” | “0”of “24” | “2”of “24” |
| Part I, 30 mg (participants) | “0”of “25” | “0”of “25” | “4”of “25” |
| Part II, 10 mg (study drug treated attacks) | “0”of “38” | “0”of “38” | “3”of “38” |
| Part II, 20 mg (study drug treated attacks) | “0”of “29” | “0”of “29” | “1”of “29” |
| Part II, 30 mg (study drug treated attacks) | “0”of “36” | “0”of “36” | “2”of “36” |
| “Part II Placebo” | “0”of “53” | “0”of “53” | “4”of “53” |
Treatment-related adverse events in the top-line data and a congress poster
Absence of injection-site reactions with oral administration
Study limitations
Summary
- The authors stated that “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity”; a higher proportion of attacks primarily in the abdominal area were treated with 10 mg than with other doses or placebo.
- Attacks with vomiting or involving the internal head or neck, including laryngeal attacks, were excluded from treatment, and “reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint”.
- The population was limited to adults aged 18 to 75 years with hereditary angioedema type 1 or 2 who were not receiving long-term prophylaxis. Patients with abnormal hepatic or renal function, users of moderate or potent CYP3A4 inhibitors or inducers, and pregnant or breastfeeding women were excluded. In the mITT analysis set, 60 (97%) of 62 participants were White.
- The primary analysis was done before all enrolled participants had treated three attacks; the final analysis of 165 attacks was descriptive. The primary efficacy analysis included 62 of 74 randomized participants, with 28 to 37 attacks per deucrictibant dose. In the registry participant flow, Part II was completed by 16 of 24, 12 of 24, and 12 of 25 participants in the 10 mg, 20 mg, and 30 mg cohorts.
- The 10 mg group had no multiplicity control and was analysed descriptively. The registry notes that within-participant correlation was not accounted for in the Kaplan-Meier medians. End of progression and outcomes by attack location were post-hoc analyses.
- TSQM and other lower-ranked secondary endpoints are to be reported elsewhere. In August 2022 the FDA placed US trials on clinical hold, and only 2 remaining US participants were permitted to complete treatment of a final attack.